Cargando…

Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma

INTRODUCTION: The presence of HER-2 has been shown to be a prognostic factor in many kinds of cancers, but its role in head and neck squamous cell carcinoma (HNSCC) is not still defined. The purpose of the current study is to investigate the role of HER-2 in HNSCC and its correlation with various cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Khademi, Bijan, Khademi, Behzad, Ghaderi, Abbas, Hosseini, Seyd Fakhroddin, Niknejad, Nika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846229/
https://www.ncbi.nlm.nih.gov/pubmed/24303437
_version_ 1782293404558819328
author Khademi, Bijan
Khademi, Behzad
Ghaderi, Abbas
Hosseini, Seyd Fakhroddin
Niknejad, Nika
author_facet Khademi, Bijan
Khademi, Behzad
Ghaderi, Abbas
Hosseini, Seyd Fakhroddin
Niknejad, Nika
author_sort Khademi, Bijan
collection PubMed
description INTRODUCTION: The presence of HER-2 has been shown to be a prognostic factor in many kinds of cancers, but its role in head and neck squamous cell carcinoma (HNSCC) is not still defined. The purpose of the current study is to investigate the role of HER-2 in HNSCC and its correlation with various clinicopathologic parameters. MATERIALS AND METHODS: Peripheral blood samples were obtained from 17 healthy volunteers and 69 patients with HNSCC before curative surgery. The HER-2 level was determined in each sample sandwich by ELISA. Statistical analysis was performed using an independent t-test, one-way ANOVA, and the Duncan procedure. RESULTS: Mean HER-2 serum levels were higher in patients with HNSCC compared with healthy controls, although the difference was not statistically significant (3.85ng/ml vs. 3.75ng/ml; P>0.05). The mean serum level of HER-2 in patients with was higher in patients with lymph node involvement, metastasis, invasion, tumor size ≥2 cm, and stage>1, although the differences were not statistically significant (P>0.05). DISCUSSION: Mean HER-2 serum levels in patients with tumor size T3 and higher were higher than those from patients in stage T1 and T2.over expression of these receptor translate into disease progression, growth and invasiveness, with the increase serum HER-2 levels in such patients offering some support for this theory. CONCLUSION: In this study the mean HER-2 serum level in patients with HNSCC was found to be greater in comparison with the healthy control group, although the difference was statistically insignificant. From the analysis of the results of the current study we have come to the conclusion that by increasing sample size the rising of the serum HER-2 level in patients with HNSCC can be meaningful. Apart from this, the role of HER-2 as a tumor marker in patients with HNSCC is still controversial and needs further studies to clarify the significance of this biomarker for early detection or screening for HNSCC.
format Online
Article
Text
id pubmed-3846229
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Mashhad University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-38462292013-12-03 Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma Khademi, Bijan Khademi, Behzad Ghaderi, Abbas Hosseini, Seyd Fakhroddin Niknejad, Nika Iran J Otorhinolaryngol Original Article INTRODUCTION: The presence of HER-2 has been shown to be a prognostic factor in many kinds of cancers, but its role in head and neck squamous cell carcinoma (HNSCC) is not still defined. The purpose of the current study is to investigate the role of HER-2 in HNSCC and its correlation with various clinicopathologic parameters. MATERIALS AND METHODS: Peripheral blood samples were obtained from 17 healthy volunteers and 69 patients with HNSCC before curative surgery. The HER-2 level was determined in each sample sandwich by ELISA. Statistical analysis was performed using an independent t-test, one-way ANOVA, and the Duncan procedure. RESULTS: Mean HER-2 serum levels were higher in patients with HNSCC compared with healthy controls, although the difference was not statistically significant (3.85ng/ml vs. 3.75ng/ml; P>0.05). The mean serum level of HER-2 in patients with was higher in patients with lymph node involvement, metastasis, invasion, tumor size ≥2 cm, and stage>1, although the differences were not statistically significant (P>0.05). DISCUSSION: Mean HER-2 serum levels in patients with tumor size T3 and higher were higher than those from patients in stage T1 and T2.over expression of these receptor translate into disease progression, growth and invasiveness, with the increase serum HER-2 levels in such patients offering some support for this theory. CONCLUSION: In this study the mean HER-2 serum level in patients with HNSCC was found to be greater in comparison with the healthy control group, although the difference was statistically insignificant. From the analysis of the results of the current study we have come to the conclusion that by increasing sample size the rising of the serum HER-2 level in patients with HNSCC can be meaningful. Apart from this, the role of HER-2 as a tumor marker in patients with HNSCC is still controversial and needs further studies to clarify the significance of this biomarker for early detection or screening for HNSCC. Mashhad University of Medical Sciences 2013-06 /pmc/articles/PMC3846229/ /pubmed/24303437 Text en © 2013: Iranian Journal of Otorhinolaryngology This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Khademi, Bijan
Khademi, Behzad
Ghaderi, Abbas
Hosseini, Seyd Fakhroddin
Niknejad, Nika
Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
title Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
title_full Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
title_fullStr Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
title_full_unstemmed Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
title_short Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
title_sort soluble her-2 in patients with head and neck squamous cell carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846229/
https://www.ncbi.nlm.nih.gov/pubmed/24303437
work_keys_str_mv AT khademibijan solubleher2inpatientswithheadandnecksquamouscellcarcinoma
AT khademibehzad solubleher2inpatientswithheadandnecksquamouscellcarcinoma
AT ghaderiabbas solubleher2inpatientswithheadandnecksquamouscellcarcinoma
AT hosseiniseydfakhroddin solubleher2inpatientswithheadandnecksquamouscellcarcinoma
AT niknejadnika solubleher2inpatientswithheadandnecksquamouscellcarcinoma